Clinical trials: Elevated Blood Pressure
Hypertension,Essential
A Study to Evaluate the Efficacy and Safety of AD-223
The purpose of this study is to evaluate the efficacy and safety of AD-223
- Trial name
- NCT06052748
- Testing
- AD-223A, AD-223B, AD-223C
- Where
- South Korea
- Volunteers
- 502 people
- Sponsor
- Addpharma Inc.
Elevated Blood Pressure
To Assess TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
The main objective of the study will be to compare the efficacy of a 2.65 g/day dose of TOTUM-854 versus placebo in decreasing SBP in subjects with high-normal blood pressure and Grade I hypertension following 12 weeks of daily…
- Trial name
- INSIGHT-2 (NCT05370625)
- Testing
- Totum-854
- Where
- Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Primary Open Angle Glaucoma (POAG)
A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial
The purpose of this study is to evaluate the long-term safety of the CyPass Micro-Stent in subjects who completed Study Protocol TMI-09-01, COMPASS Trial.
- Trial name
- COMPASS-XT (NCT02700984)
- Testing
- CyPass Micro-Stent, Cataract Surgery
- Where
- 22 sites in United States
- Volunteers
- 282 people
- Sponsor
- Alcon Research
Glaucoma
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
This will be a prospective, descriptive, mono-center, non-comparative study. A sample of 30 patients who satisfy entry criteria is estimated to be appropriate to provide safety and performance data for this study.
- Trial name
- NCT02554214
- Testing
- Glafkos drainage device
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Rheon Medical SA
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
A Open-label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin versus Co-administration of a Fixed Dose Combination of…
- Trial name
- NCT02569814
- Testing
- Fimasartan/Amlodipine/Rosuvastatin, Fimasartan/Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
Hypertension
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe…
- Trial name
- NCT00364026
- Testing
- darusentan
- Sponsor
- Gilead Sciences
Open Angle Glaucoma, Ocular Hypertension
Next Generation Rocklatan
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT06441643
- Testing
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 426 people
- Sponsor
- Alcon Research
Hypertension, Pulmonary
Pulmonary Artery Remodelling With Bosentan
The main purpose of this study is to investigate whether bosentan (Tracleer®) affects the wall thickness of the pulmonary arteries in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH related to systemic…
- Trial name
- NCT00595049
- Testing
- bosentan
- Where
- Australia
- Volunteers
- 11 people
- Sponsor
- Actelion
Primary Hypertension
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
- Trial name
- NCT06884085
- Testing
- Co-administration of AD-227A and AD-227B, Administration of AD-227
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study…
- Trial name
- NCT05459688
- Testing
- CIN-107
- Where
- 36 sites in United States
- Volunteers
- 175 people
- Sponsor
- AstraZeneca
Glaucoma
Circular Cyclocoagulation Using HIFU With EYEOP1 Device in Glaucoma Patients
The aim of the study is to evaluate the effectiveness and the safety of the cyclocoagulation using HIFU in glaucoma patients
- Trial name
- NCT01791673
- Testing
- Ultrasound glaucoma treatment
- Where
- 5 sites in France
- Volunteers
- 30 people
- Sponsor
- EyeTechCare
Open-angle Glaucoma, Ocular Hypertension
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a…
- Trial name
- NCT03822559
- Testing
- A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma
Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost
This study evaluates the efficacy and tolerability of a new formulation of latanoprost without Benzalkonium Chloride (BAK-free).
- Trial name
- NCT03331770
- Testing
- Latanoprost Ophthalmic Product
- Where
- Argentina
- Volunteers
- 103 people
- Sponsor
- Laboratorios Poen
Hypertension, MTHFR 677 TT Genotype
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype.
- Trial name
- CSPPT2-TT (NCT04974151)
- Testing
- Amlodipine besylate, Amlodipine besylate And Folic Acid, 5-methyltetrahydrofolate (5-MTHF)
- Where
- 20 sites in China
- Volunteers
- 24,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertension, Dyslipidemias
A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers
a study to investigate the pharmacokinetic characteristics and safety/tolerability according to formulations of CKD-386 in healthy male volunteers
- Trial name
- NCT03920579
- Testing
- CKD-386 formulation 1, CKD-386 formulation 2, D326, D337 and D013
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Pulmonary Hypertension
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00325442
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 354 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
This is a single center, open-label, randomized, single-dose, three-period cross-over study in healthy participants. The aim of this study is to provide clinically relevant information on the pharmacokinetic (PK) and safety…
- Trial name
- NCT04095286
- Testing
- AMB new formulation (1 mg), Reference AMB (5 mg)
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Glaucoma, Open-Angle Ocular Hypertension
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in participants with open-angle glaucoma or ocular hypertension who are not…
- Trial name
- NCT02636946
- Testing
- Bimatoprost SR, Selective Laser Trabeculoplasty
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Essential Hypertension
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.
- Trial name
- NCT02848170
- Testing
- CS-3150, olmesartan medoxomil
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.